Third degree AV block surgery
|
Third degree AV block Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Third degree AV block surgery On the Web | |
|
American Roentgen Ray Society Images of Third degree AV block surgery | |
|
Risk calculators and risk factors for Third degree AV block surgery | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Raviteja Guddeti, M.B.B.S. [3] Soroush Seifirad, M.D.[4] Qasim Khurshid, M.B.B.S [5]
Overview
Cardiac pacemakers are effective treatments for a variety of cardiac conduction abnormalities and can reestablish adequate circulation by generating appropriate heart rate and cardiac response. Two main factors guide the majority of decisions regarding permanent pacemaker insertion. First is the association of symptoms with arrhythmia, and second is the potential for progression of the rhythm disturbance.
Surgury
Recommendation for placement of permanent pacing
- Symptoms related to atrioventricular block are determining factor of placing permanent pacemaker, regardless of the level of atrioventricular block.
- Permanent pacemaker is warranted if the site of atrioventricular block is Infranodal, regardless of the presence or absence of symptoms.[1]
- Varied degree of atrioventricular block from first degree atrioventricular block to complete atrioventricular block may develope over the time in neuromuscular disorders such as muscular dystrophies or Kearns-Sayre syndrome.[2]
- Intermittent second-degree or third-degree atrioventricular block on 24-hour ambulatory electrocardiographic monitoring or atrioventricular block on resting ECG was found in 20% of patients with myotonic dystrophy type 1.
- In the presence of atrial fibrillation and slow regular ventricular response and wide QRS and pauses >3 seconds, infranodal atrioventricular block may be suspected. [3]
- Atrioventricular block may develop by using betablocker for MI or heartfailure and amiodarone and sotalol for atrial fibrillation patients.
- The benefit of using these medications should be balanced over the side effects of right ventricular pacing.[4]
- Atrioventricular block in the setting of cardiac sarcoidosis may resolve by using corticosteroids for 30 days.[5]
- Evidence of prolonged HV interval (>55 ms) despite a narrow QRS was found in AL cardiac amyloidosis.
- Mutations in the lamin A/C gene can present with atrioventricular block, atrial arrhythmias, and ventricular arrhythmia.[6]
- Risk of atrioventricular block and sudden cardiac death may increase in the setting of lamin A/C mutation.
- In one study, the risk of ventricular arrhythmias increased in the presence of first-degree atrioventricular block in lamin A/C mutation.[7]
- Pseudo-pacemaker syndrome may develop in the setting of severe first-degree atrioventricular block with very long PR interval , atrial contraction during the closed atrioventricular valves leading to an increase in wedge pressure and a decrease in cardiac output.[8]
| Recommendations for permanent pacing for chronic management of Bradycardia Attributable to Atrioventricular Block |
| (Class I, Level of Evidence B): |
|
❑Permanent pacing is recommended in patients with acquired second degree mobitz type2 atrioventricular block, high grade atrioventricular block, third degree atrioventricular block, regardless of symptoms that are not related to reversible causes |
| ( Class I, Level of Evidence C) : |
|
❑ Permanent pacing is recommended in patients with permanent atrial fibrillation and symptomatic bradycardia |
| (Class IIa, Level of Evidence B) |
|
❑ In patients with cardiac sarcoidosis and amyloidosis and evidence of mobitz type 2 atrioventricular block, high grade atrioventricular block, third degree atrioventricular block , permanent pacing with additional defibrillator capacity is reasonable if life expectancy>1 year |
| (Class IIa, Level of Evidence C) |
|
❑ In patients with symptomatic first degree atrioventricular block or motitz tyoe 1 atrioventricular block, permanent pacing is recommended |
| (Class IIb, Level of Evidence C) |
|
❑ Permanent pacing with additional defibrillator capacity is recommended in patients with neuromuscular disease including myotonic dystrophy type1 with PR interval >240ms , QRS duration >120 ms, fascicular block if life expectancy>1 year |
| The above table adopted from 2018 AHA/ACC/HRS Guideline |
|---|
Management of bradycardia or pauses attributable to chronic atrioventricular block algorithm
| Atrioventricular block | |||||||||||||||||||||||||||||||
Complete heart block (aquired)
| |||||||||||||||||||||||||||||||
| Permanent pacing (class1) | |||||||||||||||||||||||||||||||
| Consider risk for ventricular arrhythmia (class1) | |||||||||||||||||||||||||||||||
Cardiac resynchronization therapy
| |||||||||||||||||||||||||||||||
NO
| Yes
| ||||||||||||||||||||||||||||||
Yes
| N0
| ||||||||||||||||||||||||||||||
Yes
| NO
| ||||||||||||||||||||||||||||||
| LVEF>50% | |||||||||||||||||||||||||||||||
Yes
| NO
| ||||||||||||||||||||||||||||||
NO
| Yes
| ||||||||||||||||||||||||||||||
| His bundle pacing (class2b) | |||||||||||||||||||||||||||||||
| The above algorithm adopted from 2018 AHA/ACC/HRS Guideline |
|---|
Methods of implantation permanent pacing
- Common side effects of right ventricular pacing include ventricular dysfunction or heart failure symptoms.
- Risk of RV pacing-induced cardiomyopathy increases when RV pacing exceeds 40% or perhaps as low as 20%.
- CRT-P reduced left ventricular end-systolic volume and improved LVEF in comparison with RV pacing in patients with relatively preserved LVEF and LVEF<35%.
- Among patients with AF who undergo atrioventricular node ablation to control rapid ventricular rates, implantation of physiologic pacing (CRT or His bundle) was associated with improvement in 6-minute walk distances and QOL compared with RV pacing.
| Recommendations for permanent pacing techniques and methods for bradycardia associated atrioventricular block |
| (Class I, Level of Evidence A): |
|
❑ In patients with sinus node dysfunction or atrioventricular block, dual chamber permanent pacing is preferred over single chamber ventricular pacing |
| (Class I, Level of Evidence B): |
|
❑ In the presence of pacemaker syndrome in single chamber pace maker, revising single chamber pace maker to dual chamber pacemaker is recommended |
| (Class IIa, Level of Evidence B): |
|
❑Cardiac resynchronization therapy or His bundle pacing over right ventricular pacing is recommended in patients with LVEF between 36% -50 % who need more than 40% ventricular pacing |
| (Class IIb, Level of Evidence B): |
|
❑ In patients with atrioventricular block at the level of atrioventricular node, His bundle pacing may be considered for maintaining physiologic activation of ventricle |
| (Class III, Level of Evidence C): |
|
❑ For patients with permanent or persistent AF when the strategy of rhythm control is not planned, atrial lead should not be implanted |
| Recommendations for temporary pacing for bradycardia associated atrioventricular block |
| Medical therapy (Class IIa, Level of Evidence B): |
|
❑ In patients with symptomatic bradycardia associated second or third degree atrioventricular block, refractory to medications, temporary transvenous pacing is recommended to increase heart rate and improve symptoms |
Surgery
A permanent pacemaker insertion is a minimally invasive procedure. The procedure is typically performed in a cardiac catheterization lab or an operating room. Transvenous access to the heart chambers under local anesthesia is the preferred technique, most commonly via the subclavian vein, the cephalic vein, or the internal jugular vein or the femoral vein.The pacing generator is most commonly placed subcutaneously in the pre-pectoral region. Placement of pacemaker leads, surgically via thoracotomy, is rarely used these days.
Types of permanent pacemaker systems
All cardiac pacemakers consist of two components: a pulse generator that provides the electrical impulse for myocardial stimulation; and one or more electrodes that deliver the electrical impulse to the myocardium. The original cardiac pacing system was used to place surgically in the abdomen. Over time, pacemaker systems evolved to predominantly placing the pulse generator in the infraclavicular region of the chest with transvenous-placed endocardial leads. Transvenous leads have potential long-term complications, including venous thrombosis, infection, and lead malfunction. Leadless cardiac pacing systems are currently in development and offer the promise of long-term pacing capability without lead-associated complications.
Transvenous systems
The majority of cardiac pacing systems use transvenous electrodes to transmit pacing impulses from the generator to the myocardium. Transvenous leads are usually placed percutaneously or with a cephalic cutdown, without the need for intrathoracic surgery. Long term complications of transvenous electrodes include infection,venous thrombosis, lead malfunction, and tricuspid valve injury.
Epicardial systems
Epicardial cardiac pacemaker systems utilize a pulse generator with leads attached surgically directly to the epicardial surface of the heart. These systems are occasionally used in patients with vascular access problems and have been replaced by transvenous systems.
Leadless systems
In response to the limitations of existing pacings systems, leadless systems are developed. Leadless systems consist of a self-contained system that includes both the pulse generator and the electrode within a single unit that is placed into the right ventricle via a transvenous approach. Leadless cardiac pacing system was approved in April 2016 in the United States[9]
References
- ↑ Shaw DB, Kekwick CA, Veale D, Gowers J, Whistance T (June 1985). "Survival in second degree atrioventricular block". Br Heart J. 53 (6): 587–93. doi:10.1136/hrt.53.6.587. PMC 481819. PMID 4005079.
- ↑ Facenda-Lorenzo M, Hernández-Afonso J, Rodríguez-Esteban M, de León-Hernández JC, Grillo-Pérez JJ (March 2013). "Cardiac manifestations in myotonic dystrophy type 1 patients followed using a standard protocol in a specialized unit". Rev Esp Cardiol (Engl Ed). 66 (3): 193–7. doi:10.1016/j.rec.2012.08.011. PMID 24775453.
- ↑ Dhingra RC, Denes P, Wu D, Chuquimia R, Rosen KM (April 1974). "The significance of second degree atrioventricular block and bundle branch block. Observations regarding site and type of block". Circulation. 49 (4): 638–46. doi:10.1161/01.cir.49.4.638. PMID 4817704.
- ↑ Dargie HJ (September 2000). "Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction". Eur J Heart Fail. 2 (3): 325–32. doi:10.1016/s1388-9842(00)00098-2. PMID 10938495.
- ↑ Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP (January 2017). "Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival". Chest. 151 (1): 139–148. doi:10.1016/j.chest.2016.08.1457. PMID 27614001.
- ↑ van Rijsingen IA, Nannenberg EA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, van den Berg MP, Grasso M, Serio A, Jenkins S, Rowland C, Richard P, Wilde AA, Perrot A, Pankuweit S, Zwinderman AH, Charron P, Christiaans I, Pinto YM (April 2013). "Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers". Eur J Heart Fail. 15 (4): 376–84. doi:10.1093/eurjhf/hfs191. PMID 23183350.
- ↑ Hasselberg NE, Edvardsen T, Petri H, Berge KE, Leren TP, Bundgaard H, Haugaa KH (April 2014). "Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive subjects". Europace. 16 (4): 563–71. doi:10.1093/europace/eut291. PMID 24058181.
- ↑ Lader JM, Park D, Aizer A, Holmes D, Chinitz LA, Barbhaiya CR (March 2018). "Slow pathway modification for treatment of pseudo-pacemaker syndrome due to first-degree atrioventricular block with dual atrioventricular nodal physiology". HeartRhythm Case Rep. 4 (3): 98–101. doi:10.1016/j.hrcr.2017.10.003. PMC 5919070. PMID 29707483.
- ↑ http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm494390.htm